Analyst consensus rating
Immunome Analyst Rating: Strong Buy
IMNM is rated Strong Buy by 13 analysts with a $36.31 target. As of 2026-08-28.
Direct answer
Immunome's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $36.31.
Forecast evidence checked August 28, 2026.
Get free Immunome email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $28.48
- Average price target
- $36.31
- High price target
- $40.00
- Low price target
- $30.00
- Low target gap
- +5.3%
- Target upside
- +27.5%
- High target gap
- +40.4%
- Target range width
- 35.1%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Immunome?
Immunome has a verified Strong Buy consensus. The same dataset has an average price target of $36.31.
How far are Immunome's low and high targets from the recorded price?
The low target implies +5.3%, while the high target implies +40.4%.
How many analysts are included in Immunome's consensus?
The verified consensus includes 13 analysts.
How is Immunome's target upside or downside calculated?
The average target of $36.31 is divided by the recorded price of $28.48, then one is subtracted to produce +27.5%. This does not guarantee a future return.
When was Immunome's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.